Rees J K, Gray R
Semin Oncol. 1987 Jun;14(2 Suppl 1):32-6.
This trial, which will probably accrue over 1,000 patients before it closes, has already demonstrated that high remission rates are attainable in large multicenter studies using 'conventional' doses of ara-C. The results in the group aged less than 40 are comparable with many single-center studies. There is, at the moment, only a borderline difference in the remission rates between the two forms of induction therapy but the more intensive regimen of DAT 3 + 10 achieves remission more quickly and requires less supportive care. Analysis of the reasons for failure to enter remission continues to show that inadequate supportive care remains an important reason why the remission rates are not higher. Drug-related deaths in remission, though decreasing gradually in this study, are a disturbing consequence of increasing the intensity of consolidation treatment.
这项试验在结束前可能会招募超过1000名患者，它已经证明，在使用“常规”剂量阿糖胞苷的大型多中心研究中可以实现高缓解率。40岁以下组的结果与许多单中心研究相当。目前，两种诱导治疗形式之间的缓解率仅存在临界差异，但更强化的DAT 3 + 10方案能更快实现缓解，且所需的支持治疗更少。对未进入缓解期原因的分析继续表明，支持治疗不足仍然是缓解率不更高的一个重要原因。缓解期与药物相关的死亡尽管在本研究中逐渐减少，但却是强化巩固治疗带来的一个令人不安的后果。
